Members of the Epsilon team. Source: Epsilon Healthcare/LinkedIn
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Epsilon Healthcare (EPN) signs a long term manufacturing agreement for Cannim’s Jamaican cannabis products
  • The two year agreement will see Epsilon’s facility produce medical cannabis products from Cannim
  • The products created will then be supplied to the Australian market and exported around the globe
  • Epsilon was up 28 per cent and is trading at 16 cents per share at 2:53 pm AEDT

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.

Cannim is a global cannabis company with a 202 hectare farm in Jamaica.

Under the two year agreement, Epsilon’s facility will produce medical cannabis products from Cannim. The product will then be supplied to the Australian market and exported around the globe.

Under the agreement, Epsilon’s manufacturing arm, THC Pharma, will receive bulk imports of dried flower for the packaging and release of Australian GMP dried flower.

Notably, this agreement is terminable at any time by either party.

First products have already been delivered and released for patient access by Epsilon under Cannim’s HummingBud brand.

These products can be prescribed now by Tetra Health – Espilon’s wholly owned clinic network.

Cannim’s Chief Operating Officer Lachlan Cameron said the agreement allowed the company to bring its Jamaican cannabis flower to Australia.

“The high quality, GMP certified production facility will ensure that we provide the best
possible expression of our product to patients in need throughout Australia and
further afield,” he said.

Epsilon’s CEO Jarrod White is also pleased with the agreement.

“Matching our high-volume EU GMP compliant Southport Facility with Cannim’s high volume GACP Jamaican medicinal cannabis places both companies in a strong position to deliver significant volumes of high-quality medicines for both the Australian and global export markets,” Mr White said.

“The partnership contemplates all areas of the Epsilon value chain, from local import and
handling of dried product expertise, to export, and assisting in the logistics and distribution of the final product. This is reflective of the significant progress and capability
improvements at our Southport facility in the preceding 12 months.”

On the market, Epsilon was up 28 per cent and is trading at 16 cents per share at 2:53 pm AEDT.

EPN by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…